| 5LMB: reference: Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors., Garton NS, Barker MD, Davis RP, Douault C, Hooper-Greenhill E, Jones E, Lewis HD, Liddle J, Lugo D, McCleary S, Preston AG, Ramirez-Molina C, Neu M, Shipley TJ, Somers DO, Watson RJ, Wilson DM, Bioorg Med Chem Lett. 2016 Oct 1;26(19):4606-12. doi: 10.1016/j.bmcl.2016.08.070., Epub 2016 Aug 23. PMID: 27578246 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).